<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03246009</url>
  </required_header>
  <id_info>
    <org_study_id>RG01N-1399</org_study_id>
    <nct_id>NCT03246009</nct_id>
  </id_info>
  <brief_title>Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients</brief_title>
  <official_title>Efficacy and Safety Phase Ib Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin SinoBiotech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin SinoBiotech Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerance and safety of the rHSA/GCSF in breast
      cancer patients with different doses and multiple injections.

      To observe the pharmacokinetic characteristics of recombinant human serum albumin
      /granulocyte colony-stimulating factor fusion protein after single and multiple
      administration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This experiment adopts the method of multicenter, open, dose escalation study injection with
      recombinant human blood clean protein/granulocyte stimulating factor fusion protein after
      single and multiple doses of tolerance, security, and pharmacokinetic characteristics.

      Breast cancer patients with reduced white blood cells after chemotherapy were selected as
      subjects of this study.

      The three research doses that were to be incremented were 1.8 mg, 2.1mg and 2.4mg
      respectively, each of which was studied by single and multiple doses.

      Single dose of medicine, dose-climbing study.Two doses of the drug, dose-climbing study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2016</start_date>
  <completion_date type="Actual">April 10, 2017</completion_date>
  <primary_completion_date type="Actual">April 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>Number of participants with AE as a measure for safety and tolerability after single and multiple dose of rHSA/GCSF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>14 days</time_frame>
    <description>AUC after single and multiple dose of rHSA/GCSF</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chemotherapy-induced Neutropenia</condition>
  <condition>Cancer, Breast</condition>
  <arm_group>
    <arm_group_label>single injection-1.8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rHSA/GCSF,injection,1.8mg,Single subcutaneous injection,Duration 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single injection-2.1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rHSA/GCSF,injection,2.1mg,Single subcutaneous injection,Duration 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single injection-2.4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rHSA/GCSF,injection,2.4mg,Single subcutaneous injection,Duration 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple injection-1.8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rHSA/GCSF,injection,1.8mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple injection-2.1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rHSA/GCSF,injection,2.1mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>multiple injection-2.4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rHSA/GCSF,injection,2.4mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHSA/GCSF</intervention_name>
    <description>single injection-1.8mg</description>
    <arm_group_label>single injection-1.8mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHSA/GCSF</intervention_name>
    <description>single injection-2.1mg</description>
    <arm_group_label>single injection-2.1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHSA/GCSF</intervention_name>
    <description>single injection-2.4mg</description>
    <arm_group_label>single injection-2.4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHSA/GCSF</intervention_name>
    <description>multiple injection-1.8mg</description>
    <arm_group_label>multiple injection-1.8mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHSA/GCSF</intervention_name>
    <description>multiple injection-2.1mg</description>
    <arm_group_label>multiple injection-2.1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHSA/GCSF</intervention_name>
    <description>multiple injection-2.4mg</description>
    <arm_group_label>multiple injection-2.4mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65.

          -  Diagnosed breast cancer，received chemotherapy.

          -  ECOG performance status 0 or 1.

          -  ANC≥1.5×10 9/L, PLT≥100×10 9/L. No bone marrow metastasis,blood coagulation function
             normally, no Hemorrhagic tendency.

          -  Leukocyte reduction occurred after chemotherapy,WBC≤3.0x109/L or ANC≤1.5x109/L.

          -  No obvious abnormal ecg examination.

          -  Cr，TBIL, AST, ALT≤1.5×ULN，no serious underlying disease.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Chemotherapy within past 4 weeks.

          -  Uncontrolled inflammatory disease,axillary temperature≥38℃.

          -  Merging other malignant tumor.

          -  Pregnancy or nursing status.

          -  Participation in another clinical trial with and investigational product within 3
             months prior to study entry.

          -  Severe diabetes mellitus, or poor blood sugar controller.

          -  Allergic disease or allergic constitution. History of protein allergy.

          -  History of drug addiction and alcoholism.

          -  Hematopoietic stem cell transplantation or organ transplantation.

          -  Received antibiotic treatment within 72 hours before chemotherapy.

          -  Long-term use of hormones or immunosuppressive agents.

          -  Severe mental or neurological disorders.

          -  Chronic disease of severe cardiac, kidney and liver.

          -  Other conditions that would be excluded from this study according to doctors'judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe XU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>chinese academy of medical sciences tumor hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>rHSA/GCSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

